Zoetis Inc (NYSE:ZTS) has received a consensus recommendation of “Buy” from the twenty research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $79.83.
A number of equities research analysts recently issued reports on ZTS shares. Cowen set a $80.00 price target on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, November 17th. Jefferies Group reissued a “buy” rating on shares of Zoetis in a research note on Friday, November 10th. BidaskClub raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Tuesday, November 7th. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price target on shares of Zoetis in a research note on Tuesday, October 24th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $65.00 price target on shares of Zoetis in a research note on Tuesday, October 24th.
A number of hedge funds have recently made changes to their positions in ZTS. BlackRock Inc. raised its holdings in shares of Zoetis by 3.8% during the 4th quarter. BlackRock Inc. now owns 38,485,542 shares of the company’s stock worth $2,772,498,000 after acquiring an additional 1,394,156 shares during the period. Clearbridge Investments LLC raised its holdings in shares of Zoetis by 3.9% during the 4th quarter. Clearbridge Investments LLC now owns 9,512,060 shares of the company’s stock worth $685,249,000 after acquiring an additional 353,622 shares during the period. Brown Advisory Inc. raised its holdings in shares of Zoetis by 2.1% during the 4th quarter. Brown Advisory Inc. now owns 7,207,114 shares of the company’s stock worth $519,200,000 after acquiring an additional 149,095 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Zoetis by 1.5% during the 3rd quarter. Janus Henderson Group PLC now owns 5,893,853 shares of the company’s stock worth $375,792,000 after acquiring an additional 84,767 shares during the period. Finally, TIAA CREF Investment Management LLC raised its holdings in shares of Zoetis by 1.3% during the 4th quarter. TIAA CREF Investment Management LLC now owns 5,648,528 shares of the company’s stock worth $406,920,000 after acquiring an additional 73,767 shares during the period. Institutional investors own 94.18% of the company’s stock.
Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter last year, the company earned $0.47 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. sell-side analysts predict that Zoetis will post 3.02 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be issued a $0.126 dividend. The ex-dividend date is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.63%. Zoetis’s payout ratio is currently 28.57%.
TRADEMARK VIOLATION NOTICE: This story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://stocknewstimes.com/2018/02/19/zoetis-inc-zts-receives-73-72-average-price-target-from-analysts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.